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Background
Transmission of HIV-1 is highly dependent on its co-
receptor, CCR5, and humans with homozygous muta-
tions in this gene product are protected relative to hetero-
zygotes or wild type genotypes. Therefore antibodies to
CCR5 might prevent establishment of HIV infection and
help to define a potential cellular vaccine target. Here, we
evaluate the ability of HGSmAb004 and HGSmAb101,
two blocking human monoclonal antibodies to CCR5, to
prevent SHIV 162P3 infection and stimulate HIV-1
immune responses in non-human primates.
Methods
The antibodies (10-40 mg/kg) were passively adminis-
tered to rhesus macaques one day before mucosal chal-
lenge with SHIV SF162P3. Plasma viral loads, CCR5 mAb
serum levels, and receptor occupancy were monitored reg-
ularly in these monkeys. The presence of SHIV-specific
cellular immune responses was assessed in these monkeys
by intracellular cytokine staining, and anti-SHIV antibod-
ies were also detected by ELISA.
Results
Administration of HGSmAb004 reduced availability of
CCR5 receptors by 90 to 100% in recipient animals. Pas-
sive transfer of this antibody blocked SHIV infection in
two out of four monkeys and led to lower levels of viremia
in the other monkeys, whereas HGSmAb101 led to lower
viremia but not complete protection in monkeys from
SHIV162P3 infection. Infected monkeys generated anti-
SHIV specific cellular and humoral responses while unin-
fected monkeys developed little systemic long term mem-
ory T cell responses. One of the uninfected monkeys was
protected from infection when it was rechallenged with
the same virus in the absence of CCR5 mAbs and had low
levels of systemic SHIV-specific T cell responses. In con-
trast, anti-viral cellular immunity was detected at a
mucosal site by bronchoalveolar lavage.
Conclusion
Passive transfer of CCR5 antibodies can confer partial pro-
tection against a mucosal challenge with a CCR5-tropic
SHIV virus in non-human primates and may allow the
generation of anti-viral mucosal T cell immunity in pro-
tected animals.
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